Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
PTGX
Stock Latest News
The Fly
Protagonist Therapeutics price target raised to $130 from $125 at Citi
11d ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $137 from $120 at Citizens
14d ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
15d ago
PTGX
Premium
The Fly
Protagonist Therapeutics management to meet virtually with Clear Street
15d ago
PTGX
Premium
The Fly
Protagonist Therapeutics participates in a conference call with JPMorgan
15d ago
PTGX
Premium
The Fly
Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide
23d ago
TAK
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $121 from $110 at Truist
1M ago
JNJ
PTGX
Premium
Ratings
Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target
1M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $121 from $110 at Truist
1M ago
JNJ
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
2M ago
PTGX
Premium
The Fly
Protagonist price target raised to $110 from $107 at Leerink
2M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $120 from $112 at Citizens
2M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
2M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
2M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $125 from $115 at Citi
2M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $119 from $113 at Barclays
2M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
2M ago
PTGX
Premium
Ratings
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
2M ago
PTGX
Premium
The Fly
Icotyde label upside surprise for Protagonist, says H.C. Wainwright
2M ago
JNJ
PTGX
Premium
The Fly
Protagonist announces Johnson & Johnson received approval for ICOTYDE
2M ago
JNJ
PTGX
Premium
TipRanks Newswire
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
3M ago
AZN
IBO
Premium
The Fly
Protagonist Therapeutics price target raised to $95 from $65 at Goldman Sachs
3M ago
PTGX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
